Dr. Jingjing Zhu
Consultant Endocrinologist
Department of Endocrine and Metabolic Medicine
The Second Affiliated Hospital, Soochow University
E-mail：409851262@qq.com
Biography
Jingjing Zhu, MD, PhD, is a consultant endocrinologist in the Department of Endocrine and Metabolic Medicine at the Second Affiliated Hospital of Soochow University (Nuclear Industry General Hospital), China. She obtained her Bachelor’s degree in Clinical Medicine and Master’s degree in Pediatrics from Soochow University. Dr. Zhu was twice awarded competitive funding by the China Scholarship Council (CSC), in 2013 and 2022, through which she undertook doctoral and postdoctoral research in Endocrinology and Obesity at the University of Liverpool and Aintree University Hospital, United Kingdom. Since 2018, she has been working at the Second Affiliated Hospital of Soochow University, where her work focuses on the clinical management, teaching, and research of endocrine and metabolic diseases. She teaches Clinical Diagnosis to international medical students at the Medical School of Soochow University and is actively involved in the training and supervision of resident physicians in internal medicine and general practice. In recognition of her contributions to medical education, she has been awarded the title of Outstanding Teacher of the Year. Dr. Zhu leads an institutional research project and has participated in several national research programs. She has published multiple SCI-indexed papers as first author in the field of endocrinology and metabolism. She was awarded the Jiangsu Province Innovation & Career Fund (World-Class University Category) in 2019 and was selected as a Suzhou Key Medical Talent in 2022.
Research Interests
1. Mechanistic interactions between vitamin D and lipid metabolism
2. Molecular mechanisms underlying metaflammation in adipose tissue
3. Hormonal regulatory networks between obesity and metabolic homeostasis
4. Multi-omics predictive models for cardiorenal outcomes in type 2 diabetes
Select Publications (* represents corresponding author)
1. Zhu J, Wilding JPH, Hu J*. Defective lymphatic vasculature in obesity, Obes Rev. 2025, e13922.
2. Zhu JJ, Wilding JPH*, Gu XS*. Combining GLP-1 receptor agonists and SGLT-2 inhibitors for cardiovascular disease prevention in type 2 diabetes: A systematic review with multiple network meta-regressions. World J Diabetes. 2024, 15(10), 2135-2146.
3. Zhu J, Wilding JPH*. Body Fat Depletion: the Yin Paradigm for Treating Type 2 Diabetes. Curr Atheroscler Rep. 2024, 26(1), 1-10.
4. Zhu J, Wilding JPH, Hu J*. Adipocytes in obesity: A perfect reservoir for SARS-CoV-2? Med Hypotheses. 2023, 171, 111020.
5. Zhu J, Wilding JPH*. The 1alpha,25(OH)(2)D(3) Analogs ZK159222 and ZK191784 Show Anti-Inflammatory Properties in Macrophage-Induced Preadipocytes via Modulating the NF-kappaB and MAPK Signaling. Diabetes Metab Syndr Obes. 2020, 13, 1715-1724.
6. Zhu J, Bing C, Wilding JPH*. 1alpha,25(OH)(2)D(3) attenuates IL-6 and IL-1beta-mediated inflammatory responses in macrophage conditioned medium-stimulated human white preadipocytes by modulating p44/42 MAPK and NF-kappaB signaling pathways. Diabetol Metab Syndr. 2019, 11, 9.
7. Zhu J, Bing C, Wilding JPH*. Vitamin D receptor ligands attenuate the inflammatory profile of IL-1beta-stimulated human white preadipocytes via modulating the NF-kappaB and unfolded protein response pathways. Biochem Biophys Res Commun. 2018, 503(2), 1049-1056.
